Ecox
Generic Name
Etoricoxib
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| ecox 90 mg tablet | ৳ 12.04 | ৳ 120.40 |
Description
Overview of the medicine
Ecox 90 mg Tablet contains Etoricoxib, a non-steroidal anti-inflammatory drug (NSAID) specifically designed to selectively inhibit cyclooxygenase-2 (COX-2). It is used to relieve pain and reduce inflammation and swelling in various conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gouty arthritis, and for the short-term treatment of moderate acute pain, including dental surgery pain.
Uses & Indications
Dosage
Adults
Osteoarthritis: 30-60 mg once daily. Rheumatoid Arthritis, Ankylosing Spondylitis: 60-90 mg once daily. Acute Gouty Arthritis, Acute Pain (including post-surgical dental pain): 120 mg once daily for a maximum of 8 days. The lowest effective dose should be used for the shortest duration.
Elderly
No dose adjustment is generally required based on age, but caution is advised in elderly patients due to increased risk of adverse effects, especially cardiovascular and gastrointestinal events. Monitoring is recommended.
Renal_impairment
Severe renal impairment (creatinine clearance <30 mL/min) is contraindicated. For moderate renal impairment (creatinine clearance 30-60 mL/min), the maximum dose is 60 mg once daily. For mild renal impairment, no dose adjustment is necessary.
How to Take
Ecox 90 mg Tablet should be taken orally, once daily. It can be taken with or without food. Swallow the tablet whole with a sufficient amount of water.
Mechanism of Action
Etoricoxib is a highly selective inhibitor of cyclooxygenase-2 (COX-2) enzyme. COX-2 is primarily responsible for the synthesis of prostaglandins, which are key mediators of pain, inflammation, and fever. By selectively inhibiting COX-2, Etoricoxib reduces prostaglandin production, thereby exerting its analgesic, anti-inflammatory, and antipyretic effects while minimizing gastrointestinal side effects associated with non-selective NSAIDs.
Pharmacokinetics
Onset
Onset of analgesia is typically observed within 24 minutes for acute pain. For chronic conditions, clinical benefit begins within 2 weeks.
Excretion
Approximately 70% of the dose is excreted in the urine and 30% in the feces, predominantly as metabolites. Less than 1% of the dose is excreted unchanged in urine.
Half life
The mean elimination half-life is approximately 22 hours, supporting once-daily dosing.
Absorption
Rapidly absorbed after oral administration, with peak plasma concentrations (Cmax) achieved in approximately 1 hour. The oral bioavailability is approximately 100%.
Metabolism
Extensively metabolized in the liver, primarily by cytochrome P450 (CYP) enzymes, particularly CYP3A4, to inactive metabolites.
Side Effects
Contraindications
- •Hypersensitivity to etoricoxib or any component of the tablet
- •Active peptic ulceration or gastrointestinal bleeding
- •Inflammatory bowel disease
- •Severe hepatic dysfunction (Child-Pugh score ≥10)
- •Severe renal dysfunction (creatinine clearance <30 mL/min)
- •Congestive heart failure (NYHA II-IV)
- •Established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease
- •Uncontrolled hypertension
- •Pregnancy and lactation
Drug Interactions
Lithium
May increase plasma lithium levels, leading to toxicity. Monitor lithium levels closely.
Warfarin
May enhance the anticoagulant effect of warfarin, increasing the risk of bleeding. Close INR monitoring is recommended.
Methotrexate
May increase plasma concentrations of methotrexate, enhancing its toxicity. Caution and monitoring are advised.
Oral Contraceptives
May increase plasma concentrations of ethinyl estradiol, potentially increasing the risk of adverse events associated with oral contraceptives.
Cyclosporine/Tacrolimus
May increase the nephrotoxic effect of these immunosuppressants.
Diuretics, ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs)
May reduce the antihypertensive effect of these medications and increase the risk of renal impairment, especially in dehydrated or elderly patients.
Storage
Store in a cool, dry place, below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
In case of overdose, no specific antidote is available. Management should be symptomatic and supportive. Standard measures such as gastric decontamination (e.g., activated charcoal or gastric lavage) may be considered, especially if the overdose is recent. Close monitoring of vital signs and renal function is crucial.
Pregnancy & Lactation
Etoricoxib is contraindicated during pregnancy, especially in the third trimester, due to the potential for premature closure of the ductus arteriosus and impaired renal function in the fetus. It is also contraindicated during lactation as it is excreted in breast milk and could potentially harm the nursing infant.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2 to 3 years from the date of manufacture when stored under recommended conditions.
Availability
Pharmacies, Hospitals
Approval Status
Approved by regulatory authorities (e.g., EMA, DGDA)
Patent Status
Generic available, patent expired in many regions
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
